NTI 2.78% 7.0¢ neurotech international limited

Ann: Neurotech Receives Additional HREC Approval in Autism, page-2

  1. 11,748 Posts.
    lightbulb Created with Sketch. 5949
    Dr Thomas Duthy, Executive Director of Neurotech said “We thank the Monash HREC for this extension,
    which provides comfort to our Phase I/II trial participants that they are able to receive NTI164 therapy
    for an additional 52 weeks above existing approvals. We continue to focus our resources on
    completing the current Phase II/III ASD trial and remain on track to report the results of our Phase II/III
    ASD trial in late Q1 CY2024 to early Q2 CY2024.”


 
watchlist Created with Sketch. Add NTI (ASX) to my watchlist
(20min delay)
Last
7.0¢
Change
-0.002(2.78%)
Mkt cap ! $71.21M
Open High Low Value Volume
7.3¢ 7.3¢ 7.0¢ $86.59K 1.228M

Buyers (Bids)

No. Vol. Price($)
1 6000 7.1¢
 

Sellers (Offers)

Price($) Vol. No.
7.5¢ 72226 1
View Market Depth
Last trade - 15.38pm 28/06/2024 (20 minute delay) ?
NTI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.